ResearcherTaizhou Central HospitalActive in the last 2 years

Hao Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4123-4930; OpenAlex author ID A5100729491. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Downregulation of miR-503-5p Promotes the Development of Pancreatic Cancer by Targeting Cyclin E2. Co-author DOI 10.1615/critrevimmunol.2024051136 ↗
Nobiletin flavone inhibits the growth and metastasis of human pancreatic cancer cells via induction of autophagy, G0/G1 cell cycle arrest and inhibition of NF-… Co-author PMID 32521908 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Fei Li · 1 shared paper, 2024 · strength 0.26
- Paper Downregulation of miR-503-5p Promotes the Development of Pancreatic Cancer by Targeting Cyclin E2. DOI 10.1615/critrevimmunol.2024051136 ↗
Jie Zhu · 1 shared paper, 2024 · strength 0.26
- Paper Downregulation of miR-503-5p Promotes the Development of Pancreatic Cancer by Targeting Cyclin E2. DOI 10.1615/critrevimmunol.2024051136 ↗
Jinggang Mo · 1 shared paper, 2020 · strength 0.15
- Paper Nobiletin flavone inhibits the growth and metastasis of human pancreatic cancer cells via induction of autophagy, G0/G1… PMID 32521908 ↗
Haiou Wang · 1 shared paper, 2020 · strength 0.15
- Paper Nobiletin flavone inhibits the growth and metastasis of human pancreatic cancer cells via induction of autophagy, G0/G1… PMID 32521908 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.